FDA Approves World’s First Interoperable Insulin Pump for Personalized Diabetes Management

VCBeat (WeChat ID: vcbeat) has learned that on February 14, the U.S. Food and Drug Administration (FDA) granted marketing approval for the t:slim X2, the first insulin pump featuring interoperable technology. Developed by Tandem Diabetes Care, this insulin pump is designed to deliver subcutaneous insulin injections to children and adults with diabetes.

This new type of insulin pump, known as the Alternate Controller Enabled (ACE) infusion pump or interoperable insulin pump, is the first interoperable insulin pump. This means it can be used with various components that make up a diabetes treatment system, allowing patients to adjust their diabetes management devices according to personal preferences. The diabetes treatment system consists of the ACE insulin pump and other compatible medical devices, including Automated Insulin Delivery (AID) systems, Continuous Glucose Monitors (CGMs), blood glucose meters, and other electronic devices for diabetes management.

“Diabetes is a complex disease that requires close monitoring and carefully tailored treatment. We have heard from the patient community that the ability to customize their diabetes management devices is very important to them. Advances in digital health have made personalized diabetes care possible,” said FDA Commissioner Dr. Scott Gottlieb. “The marketing authorization of the first ACE insulin pump with interoperable technology opens the door for developers of future connected diabetes devices, enabling them to provide safer and more effective products for patients and helping individuals with diabetes pursue more personalized treatment approaches.”

This interoperable insulin pump helps patients achieve personalized diabetes management (Image source: Tandem Diabetes Care official website)

Dr. Scott Gottlieb stated, “By creating a new regulatory classification, the FDA will enable ACE insulin pumps to navigate the 510(k) review process more efficiently in the future, thereby helping to advance this new technology (interoperable technology). We are committed to supporting medical R&D institutions in accelerating the development of innovative approaches to improve patient care, while also strengthening pre-market and post-market testing tools to determine the safety and effectiveness of these new technologies.”

Data show that nearly 10% of Americans have been diagnosed with diabetes, a condition that impairs the body’s ability to produce or properly use insulin, the hormone that regulates blood glucose.

The interoperable t:slim X2 insulin pump works by delivering insulin subcutaneously at a fixed or variable rate. It can automatically communicate with other diabetes management devices, such as Automated Insulin Delivery (AID) systems, via digital connectivity and receive medication dosing commands. When not connected to other devices, the interoperable t:slim X2 pump can administer insulin independently. An AID system typically consists of an insulin pump, a continuous glucose monitor (CGM), and control system software.

To date, insulin pumps have received FDA approval either as standalone devices (Class II, moderate-risk devices) or as part of a single, pre-defined diabetes management system (Class III, highest-risk devices). As the interoperable t:slim X2 insulin pump can interoperate with other components of diabetes care systems, it is subject to review via the Premarket Review pathway, which is the regulatory route for novel low-to-moderate risk devices.

Meanwhile, the FDA is developing a standard known as “special controls,” which outlines requirements to ensure the accuracy, reliability, cybersecurity, and clinical relevance of ACE infusion pumps, and describes the types of studies and data needed to demonstrate acceptable pump performance. When used in conjunction with general controls, these special controls provide reasonable assurance of the safety and effectiveness of such devices.

The FDA reviewed the performance data of the interoperable t:slim X2 pump, demonstrating that the device can accurately and reliably deliver insulin to patients at user-set rates and volumes. The FDA also evaluated the pump’s ability to communicate with external devices possessing appropriate reliability, cybersecurity, and fail-safe modes.

Risks associated with the use of the interoperable T:slim X2 pump are similar to those of other infusion pumps and may include infection, bleeding, pain, or skin reactions (such as redness, swelling, bruising, itching, scarring, or skin discoloration). Other risks may include tubing occlusion and air bubble formation, which can affect medication delivery. Risks associated with incorrect medication delivery include hypoglycemia (low blood sugar), hyperglycemia (high blood sugar), and potentially diabetic ketoacidosis.

Risks associated with connected ACE insulin pumps may include medication delivery errors resulting from loss of communication between devices (e.g., the pump receiving erroneous commands or experiencing cybersecurity vulnerabilities).

(Compiled by Cheng Xiaoqin)